The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response

Nature Immunology

Volumn 15, Issue 8, 2014, Pages 738-748

  Baroja Mazo, Alberto ^a   Martín Sánchez, Fatima ^a   Gomez, Ana I ^a   Martínez, Carlos M ^a   Amores Iniesta, Joaquín ^a   Compan, Vincent ^b,g   Barberà Cremades, Maria ^a   Yagüe, Jordi ^c   Ruiz Ortiz, Estibaliz ^c   Antón, Jordi ^d   Buján, Segundo ^e   Couillin, Isabelle ^f   Brough, David ^b   Arostegui, Juan I ^c   Pelegrín, Pablo ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL SANT JOAN DE DÉU   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Laboratoire d'Immunologie et Embryologie Moleculaires Orleans   (France)

^g UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CINCA SYNDROME; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOBLOTTING; INFLAMMATION; MACROPHAGE; MOUSE; MUTANT; NONHUMAN; PARTICULATE MATTER; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN SECRETION;

ANIMALS; CARRIER PROTEINS; CASPASE 1; CASPASES; CELLS, CULTURED; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; CYTOSKELETAL PROTEINS; HEK293 CELLS; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHAGOCYTOSIS; SIGNAL TRANSDUCTION;

EID: 84904646033     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.2919     Document Type: Article

References (49)

1. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27, 519-550 (2009).
2. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
3. Lopez-Castejon, G. & Brough, D. Understanding the mechanism of IL-1 secretion. Cytokine Growth Factor Rev. 22, 189-195 (2011).
4. Dinarello, C.A., Donath, M.Y. & Mandrup-Poulsen, T. Role of IL-1 in type 2 diabetes. Curr. Opin. Endocrinol. Diabetes Obes. 17, 314-321 (2010).
5. Neven, B. et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 103, 2809-2815 (2004).
6. Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006).
7. Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357-1361 (2010).
8. Cai, X. et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasomeactivation. Cell 156, 1207-1222 (2014).
9. Lu, A. et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193-1206 (2014).
10. Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228-232 (2006).
11. Compan, V. et al. Cell volume regulation modulates NLRP3 inflammasome activation. Immunity 37, 487-500 (2012).
12. Halle, A. et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9, 857-865 (2008).
13. Babelova, A. et al. Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors. J. Biol. Chem. 284, 24035-24048 (2009).
14. Yazdi, A.S. et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1 and IL-1. Proc. Natl. Acad. Sci. USA 107, 19449-19454 (2010).
15. Eisenbarth, S.C., Colegio, O.R., O'Connor, W., Sutterwala, F.S. & Flavell, R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122-1126 (2008).
16. Rajamäki, K. et al. Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome. J. Biol. Chem. 288, 13410-13419 (2013).
17. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847-856 (2008).
18. Lopez-Castejon, G. et al. Deubiquitinases regulate the activity of caspase-1 and interleukin-1 secretion via assembly of the inflammasome. J. Biol. Chem. 288, 2721-2733 (2013).
19. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
20. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136-140 (2009).
21. Muñoz-Planillo, R. et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142-1153 (2013).
22. Murakami, T. et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. USA 109, 11282-11287 (2012).
23. Lamkanfi, M. et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 185, 4385-4392 (2010).
24. Keller, M., Rüegg, A., Werner, S. & Beer, H.-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132, 818-831 (2008).
25. Pétrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007).
26. Kahlenberg, J.M., Lundberg, K.C., Kertesy, S.B., Qu, Y. & Dubyak, G.R. Potentiation of caspase-1 activation by the P2X7 receptor is dependent on TLR signals and requires NF-B-driven protein synthesis. J. Immunol. 175, 7611-7622 (2005).
27. Miao, E.A., Rajan, J.V. & Aderem, A. Caspase-1-induced pyroptotic cell death. Immunol. Rev. 243, 206-214 (2011).
28. Masters, S.L., Simon, A., Aksentijevich, I. & Kastner, D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27, 621-668 (2009).
29. Gross, O. et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36, 388-400 (2012).
30. Miao, E.A. et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11, 1136-1142 (2010).
31. Balci-Peynircioglu, B. et al. Expression of ASC in renal tissues of familial mediterranean fever patients with amyloidosis: postulating a role for ASC in AA type amyloid deposition. Exp. Biol. Med. (Maywood ) 233, 1324-1333 (2008).
32. Shi, C.S. et al. Activation of autophagy by inflammatory signals limits IL-1 production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255-263 (2012).
33. Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat. Immunol. 12, 222-230 (2011).
34. Dupont, N. et al. Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1. EMBO J. 30, 4701-4711 (2011).
35. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
36. Shmagel, K.V. & Chereshnev, V.A. Molecular bases of immune complex pathology. Biochemistry (Mosc.) 74, 469-479 (2009).
37. Kahlenberg, J.M., Carmona-Rivera, C., Smith, C.K. & Kaplan, M.J. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J. Immunol. 190, 1217-1226 (2013).
38. Garcia-Calvo, M. et al. Purification and catalytic properties of human caspase family members. Cell Death Differ. 6, 362-369 (1999).
39. Fernandes-Alnemri, T. et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14, 1590-1604 (2007).
40. Masters, S.L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 in type 2 diabetes. Nat. Immunol. 11, 897-904 (2010).
41. Tanaka, N. et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 63, 3625-3632 (2011).
42. Nakagawa, K. et al. Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2013-204361 (10 December 2013).
43. Hoffman, H.M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004).
44. Hoffman, H.M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452 (2008).
45. Lachmann, H.J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425 (2009).
46. Adamczak, S. et al. Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J. Neurosurg. 117, 1119-1125 (2012).
47. Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213-218 (2004).
48. Kuida, K. et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 267, 2000-2003 (1995).
49. Fernandes-Alnemri, T. & Alnemri, E.S. Assembly, purification, and assay of the activity of the ASC pyroptosome. Methods Enzymol. 442, 251-270 (2008).